NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society

NewCardio, Inc., a cardiac diagnostic technology provider, announced that two of its recent medical and technical submissions have been accepted for their presentations at the 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society conference. The two papers: 'Wireless Monitoring of Reconstructed 12-Lead ECG in Atrial Fibrillation Patients Enables Differential Diagnosis of Recurrent Arrhythmias' and 'Algorithm for Quantitative 3-Dimensional Analysis of ECG Signals Improves Myocardial Diagnosis Over Cardiologists in Diabetic Patients', will be presented during the conference to be held September 1-4, in Boston, Massachusetts. NewCardio scientists and their academic medical collaborators will present data from recently completed clinical studies that highlight the diagnostic potentials of two company products, CardioBip™ and my3KG™: * The first of these studies showed that CardioBip accurately captured, wirelessly transmitted, and reconstructed full 12-lead ECG data from patients with atrial fibrillation (AF) who had previously undergone a therapeutic catheter ablation procedure. Such patients are at significant risk for stroke from recurrent bouts of AF; moreover, currently available cardiac monitoring techniques all have significant limitations for recurrent AF detection that may be addressed by long-term CardioBip monitoring. The NewCardio-sponsored study showed that (1) post-ablation AF patients could conveniently monitor themselves for recurrent AF with CardioBip for the entire duration of the study (6 months); (2) CardioBip frequently detected AF recurrences, whether the patient had symptoms or not; and (3) CardioBip was substantially more sensitive and accurate than periodic sustained (12-lead 24 hours Holter) monitoring in detecting recurrent AF. * The second study showed that my3KG was substantially more sensitive and accurate than the standard 12-lead electrocardiogram in diagnosing acute heart attack (myocardial infarction, or MI) in patients with Type II diabetes mellitus (Type II DM). This is a significant and important advance because Type II DM is a large and growing patient population with a high risk of MI, and a population in which an accurate MI diagnosis is notoriously difficult to obtain. "This now marks the third consecutive year this prestigious medical conference has accepted two of our papers for presentation," said Dorin Panescu, PhD, Chief Technical Officer of NewCardio and a Fellow of the IEEE. "The acceptance of these submissions reflects the growing recognition of the quality and innovative nature of our science and technology, and that they meet important and previously unmet medical needs." The conference program will consist of plenary lectures, symposia, workshops and invited sessions of the latest significant findings and developments in all the major fields of biomedical engineering. Submitted papers were peer reviewed. The NewCardio studies will be presented in oral sessions at the IEEE meeting, and will appear in the Conference Proceedings, which are indexed in PubMed/MEDLINE.